Peptide Therapy: What the Research Says
Reviewed by LeoCore Health clinical team — for informational and research purposes only. October 2026
Peptide therapy has attracted significant research interest over the past two decades. While many peptides remain in the investigational stage, a growing body of preclinical and clinical evidence supports their use in targeted, physician-supervised protocols. The following is an overview of the research landscape for the peptides most commonly used at LeoCore Health.
BPC-157 (Body Protection Compound-157)
Tissue repair & gut health
BPC-157 is a synthetic peptide derived from a protein found in gastric juice. Preclinical studies have demonstrated its ability to accelerate healing of tendons, ligaments, muscles, and the gastrointestinal tract. Research published in the Journal of Physiology-Paris and other peer-reviewed journals suggests BPC-157 promotes angiogenesis (new blood vessel formation) and modulates nitric oxide pathways — mechanisms that may underlie its observed tissue-repair effects. Animal studies have consistently shown accelerated recovery from muscle tears, tendon damage, and intestinal injury. Human clinical data is limited but emerging, and the peptide is currently used in physician-supervised protocols where the risk-benefit profile is evaluated individually.
TB-500 (Thymosin Beta-4)
Cell migration & inflammation
Thymosin Beta-4 is a naturally occurring peptide present in virtually all human and animal cells. It plays a central role in cell migration, proliferation, and differentiation — processes essential to wound healing and tissue regeneration. Research has shown TB-500 to upregulate actin, a protein critical to cell movement, and to reduce inflammatory cytokines in damaged tissue. Studies in animal models have demonstrated accelerated healing of cardiac tissue, corneal injuries, and skin wounds. TB-500 is used in physician-supervised protocols for patients with chronic injury or inflammatory conditions, with dosing and monitoring tailored to individual health status.
CJC-1295 / Ipamorelin
Growth hormone stimulation
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue. Used in combination, they stimulate the pituitary gland to release growth hormone in a pulsatile, physiologically natural pattern — mimicking the body's own release cycles rather than flooding the system with exogenous hormone. Clinical research on GHRH analogues has demonstrated improvements in lean body mass, fat reduction, sleep quality, and recovery in both aging populations and athletes. The combination is favored in longevity protocols for its favorable safety profile relative to direct growth hormone administration.
The information on this page is intended for educational purposes only and does not constitute medical advice. Compounded peptide medications have not been evaluated by the FDA for safety or effectiveness. Individual results vary. Treatment is only prescribed when clinically appropriate following a licensed provider evaluation.
Ready to Take the Next Step?
Start with a confidential online evaluation. Our physicians will review your health history and goals to recommend the right treatment path for you.
Comments